EUVIMEDEUVIMED entdecken
Crossref

QbD Based Formulation, Optimization and Characterization of Diosgenin and Psoralen Nanoemulgel for Psoriasis

Sandhya Sharma, Nayyar Parvez, Amarjeet Singh

International Journal of Drug Delivery Technology · 09.06.2026 · 16 (51s)

DOI: 10.25258/ijddt.16.51s.90 ↗

Kurz gefasst

Fachartikel in der Zeitschrift International Journal of Drug Delivery Technology, online erschienen am 09.06.2026. Verfasst von Sandhya Sharma und 2 weiteren Autor:innen.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Psoriasis is a chronic inflammatory skin disorder which causes excessive proliferation and abnormal differentiation of keratinocytes. Traditional remedies often exhibit constraints, including systemic adverse effects, inadequate skin absorption, and diminished patient adherence. This work intended to create an innovative nanoemulgel system coloaded with Diosgenin and Psoralen, two phytoconstituents with established anti-psoriatic efficacy, using a Quality by Design (QbD) methodology to solve these obstacles. This work investigates a nanoformulation method for creating a Diosgenin and Psoralen nanoemulsion gel (NEG-2) to boost solubility and improve absorption. The chosen excipients, surfactant/co-surfactant, and oil for the o/w nanoemulsion (NE-G) are Tween 80/Transcutol-P and olive oil. The formulation process employs high-energy ultrasonication with a three-dimensional factorial Box–Behnken design for systematic optimization. The generated nanoemulsion has a 50 nm spherical, globule-like shape, according to the evaluation of its surface morphology using fluorescence microscopy and scanning/transmission electron microscopy. The optimized NE-G exhibited a zeta potential of −25.23 ± 0.18 mV, a size of 195.5 ± 2.65 nm, a polydispersity index (PDI) of 0.37 ± 0.021, and a pH of 5.9 ± 0.34. The improved NE-G was then synthesized into a gel with 1% Carbopol 971®. The in vitro release investigation of the improved NEG-2 demonstrated a diffusion-dominant drug release, as per the Higuchi model, during a 24-hour period. The modified nanoemulgel exhibited improved skin penetration, regulated release, and a significant decrease in psoriatic symptoms, validating its potential as an efficacious topical treatment.ThisQbD-guided methodology guaranteed repeatability, scalability, and robustness of the formulation, creating a potential platform for the administration of herbal actives in the therapy of psoriasis

Zitieren

APA

Sharma, S., Parvez, N., & Singh, A. (2026). QbD Based Formulation, Optimization and Characterization of Diosgenin and Psoralen Nanoemulgel for Psoriasis. International Journal of Drug Delivery Technology, 16(51s). https://doi.org/10.25258/ijddt.16.51s.90

Vancouver

Sharma S, Parvez N, Singh A. QbD Based Formulation, Optimization and Characterization of Diosgenin and Psoralen Nanoemulgel for Psoriasis. International Journal of Drug Delivery Technology. 2026;16(51s). doi:10.25258/ijddt.16.51s.90

BibTeX
@article{Sharma2026,
  author = {Sharma, Sandhya and Parvez, Nayyar and Singh, Amarjeet},
  title = {QbD Based Formulation, Optimization and Characterization of Diosgenin and Psoralen Nanoemulgel for Psoriasis},
  journal = {International Journal of Drug Delivery Technology},
  year = {2026},
  volume = {16},
  number = {51s},
  doi = {10.25258/ijddt.16.51s.90}
}
Kostenlos starten →